---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211918"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:49:44.024741+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility

## Summary
- Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.
- Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.
- Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.
- ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.
- R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions.

## SEC filing metadata
- accession: 0001193125-26-211918
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/0001193125-26-211918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/alec-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211918
- JSON: https://secwatch.observer/filing/0001193125-26-211918.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211918.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported the quarter ended March 31, 2026 results: revenue $1.0 million, net income $22.9 million, EPS $0.21 per share.
  - Period: the quarter ended March 31, 2026
  - Revenue: $1.0 million
  - Net income: $22.9 million
  - EPS: $0.21 per share
  - Result: reported results
  source text: Revenue. Collaboration revenue for the quarter ended March 31, 2026, was $1.0 million, compared to $3.7 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/0001193125-26-211918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.